Αναζήτηση Δραστικών

INTERFERON BETA-1A

ATC

Εμπορικές Ονομασίες

  • AVONEX
    Μορφές: INJ.SOL
  • REBIF
    Μορφές: INJ.SOL
  • DRUGBANK - Interferon beta-1a
  • indication:

    For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum

  • pharmacology:

  • mechanism:

    Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.

  • toxicity:

  • absorprion:

  • halflife:

    10 hrs

  • roouteelimination:

  • volumedistribution:

  • clearance:

    * 33-55 L/hour [Healthy SC injection of 60 mcg]